News

Read the latest updates about BioMarin and learn more about our science, our people and the communities we support.

Why Do I Pheel This Way?

Community

Why Do I Pheel This Way? New Video Podcast Series Sheds Light on Navigating Adolescence with Phenylketonuria

May 28, 2026

Monica Mann presenting on stage

Monica Mann Reflects on a Life Dedicated to Healthcare Transformation

April 30, 2026

Carissah and Angela

Community

Crossing Paths: How the National MPS Society Reaches Families Where They Are

May 13, 2026

Stories

All Stories

Why Do I Pheel This Way? Episode 2

Community

Why Do I Pheel This Way? Episode 2 Explores Social Life, Support and Self-Advocacy for Teens with Phenylketonuria

June 11, 2026

DNA of BioMarin Kim Warner

Kim Warner Builds Pathways for Early-Career Professionals Seeking Mission-Driven Opportunities

May 29, 2026

Why Do I Pheel This Way?

Community

Why Do I Pheel This Way? New Video Podcast Series Sheds Light on Navigating Adolescence with Phenylketonuria

May 28, 2026

Carissah and Angela

Community

Crossing Paths: How the National MPS Society Reaches Families Where They Are

May 13, 2026

Savannah and her mom, DeAnna

Community

Finding a Way Forward: How the National MPS Society’s Pathways Program Supports Families at Diagnosis

May 6, 2026

Monica Mann presenting on stage

Monica Mann Reflects on a Life Dedicated to Healthcare Transformation

April 30, 2026

Press Releases

All Press Releases

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

May 20, 2026

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency

May 18, 2026

BioMarin Reports First Quarter 2026 Financial and Operating Results

May 4, 2026

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society’s 2026 Annual Meeting

May 2, 2026

BioMarin Completes Acquisition of Amicus Therapeutics

April 27, 2026

Company Statements

All Company Statements